Hillrom to acquire Breathe Tech and its wearable ventilator for $130M

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio. (Kritchanut/iStock/Getty Images Plus/Getty Images)

Hillrom has moved to pick up former Fierce 15 winner Breathe Technologies, maker of a wearable ventilator for people with lung conditions such as chronic obstructive pulmonary disease. 

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio, broadening the company’s reach in COPD as well as interstitial lung disease, restrictive thoracic disorder and rehabilitation following a lung transplant.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The ventilator unit, which weighs about a pound, can be worn on a belt or waistband and has a four-hour battery life. It can be connected to a separate, stationary compressor for use inside the home, with tubing up to 50 feet long, or used alone outside the home while connected to an alternate pressure source.

RELATED: FierceMedicalDevices’ 2014 Fierce 15 | Breathe Technologies

"The acquisition of a highly differentiated, wearable non-invasive ventilation technology provides an exciting growth platform that utilizes our direct Respiratory Care commercial channel and business model," Hillrom President and CEO John Groetelaars said in a statement. 

Breathe's Life2000 ventilator
and compressor. (Breathe)

RELATED: Hillrom debuts new handheld telehealth eye camera for diabetic retinopathy screening

"This transaction represents another example of our plan to strategically deploy capital with a disciplined approach toward higher-growth and higher-margin businesses by expanding into the disruptive new category of non-invasive ventilation," Groetelaars added. 

Hillrom expects to close the deal during the fourth quarter of its 2019 fiscal year. The other products in its respiratory portfolio include a variety of airway clearance systems, including wearable and acute care versions, as well as nebulizer support.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.